Literatur
-
01 Neumeyer G., Hrsg). Thymuspeptide zur Behandlung chronischer und maligner Erkrankungen. Karl F. Haug Verlag Heidelberg; 1996
-
02 Maurer H. R., Goldstein A. L., Hager E. D.. Thymic peptides in preclinical and clinical medicine. W. Zuckschwerdt Verlag München, Bern, Wien, New York; 1997
-
03
Low T. L. K., Goldstein A. L..
Thymosins: structure, function and therapeutic applications.
Thymus.
6
1984;
27-32
-
04
Ben-Efraim S., Keisari Y., Ophir R., Pecht M., Trainin N., Burstein Y..
Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on Thymic Humoral Factor (THF-γ-2).
Critical Rev Immunol.
19
1999;
261-284
-
05
Beuth J., Schierholz J. M., Ko H. L., Braun J. M..
Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice.
In Vivo.
15
2001;
403-406
-
06
Mayer G., Pohlmeyer K., Caliebe A., Heimüller E., Behnke B., Steinmann G., Lange C., Beuth J..
Low molecular thymic peptides stimulate human blood dendritic cells.
Anticancer Res.
20
2000;
2873-2884
-
07
Ernst E..
Thymus therapy for cancer? A criteria-based, systemic review.
Eur J Cancer.
33
1997;
531-535
-
08
Cassileth B. R..
Thymus therapy for cancer.
Eur J Cancer.
33
1997;
517-518
-
09
Pavesi L..
Fluorouracil with and without high-dose folinic acid plus epirubicin and cyclophosphamide (FEC) versus HDFA-FEC plus or minus thymustimulin in metastatic breast cancer. Results of a multicenter study.
Eur J Cancer.
29
1993;
77-80
-
10
Mustacchi G., Pavesi L., Milani S., Iaffaioli V.. et al. .
High-dose folinic acid and fluorouracil plus or minus thymostimulin for treatment of metastatic colorectal cancer. Results of a randomized multicenter clinical trial.
Anticancer Res.
14
1994;
617-620
-
11
Federico M., Gobbi P. G., Mretti G., Avanzini P., Di Renzo N., Cavanna L., Ascari E., Siligardi V..
Effects of thymuostimulin with combination chemotherapy in patients with aggressive Non Hodgkin Lymphoma.
Am J Clin Oncol.
18
1995;
8-14
-
12
Scheer H. I., Shank B., Chapman R., Geller N., Pinsky C., Gialla R., Kelsen D., Bosl G., Golbey R., Petroni G..
Randomized trial of combined modality therapy with and withour Thymosin fraction V in treatment of small cell lung cancer.
Cancer Res.
481
1988;
1663-1670
-
13
Mallmann P., Krebs D..
Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotheraoy with thymopentin.
Exp Clin Pharmacol.
12
1990;
333-340
-
14
Mayer G., Wolf F., Schmidt U. J..
Erste placebokontrollierte Doppelblindstude mit Thymuspeptiden bei Patienten mit metastasiertem kolorektalen Karzinom in Deutschland.
Z Onkol/J of Oncol.
31
1999;
8-13
Korrespondenzadresse:
Prof. Dr. Josef Beuth
Institut zur wissenschaftlichen Evaluation naturheilkundlicher Verfahren Universität zu Köln
Robert-Koch-Str. 10
50931 Köln
